




版权说明:本文档由用户提供并上传,收益归属内容提供方,若内容存在侵权,请进行举报或认领
文档简介
Financialanalysiscoursework
GuangzhouBaiyunshanPharmaceuticalCo.,Ltd.2010AnnualReportAnalysis————InternationalInstituteofAccounting0803
Financialanalysiscoursework1TeammembersTeammembers2AnalysisOutline1.Introduction2.Commonratioanalysis3.RelatedRatioAnalysis4.ComparativeAnalysisofcompetitors5.ConclusionsAnalysisOutline1.Introducti31.Introduction(1)BasicinformationofcompanyChineseCompanyName:GuangzhouBaiyunshanPharmaceuticalCo.,Ltd.NameinEnglish:GuangzhouBaiyunshanPharmaceuticalCo.,Ltd.Chineseabbreviationofthecompany:BaiyunshanPharmaceuticalCompanyabbreviation:BYSLegalrepresentative:Mr.XieBinBoardSecretary:Mr.QiaoYongAddress:BaiyunDistrict,GuangzhouCity,GuangdongProvince,andthestreetwith88YunxiangRoadPhoneax:020-87,063,699E-mail:qiaoyong@SecuritiesAffairsRepresentative:MissGaoYanzhuAddress:BaiyunDistrict,GuangzhouCity,GuangdongProvince,andthestreetwith88YunxiangRoadPhoneax:020-87,063,699E-mail:gyzh2611@126.com1.Introduction(1)Basicinfor41.Introduction(2)CompanyBusinessDescriptionGuangzhouBaiyunshanPharmaceuticalCo.,Ltd.Establishedin1973,1992,GuangzhouMunicipalPeople'sGovernmentof11menstrualapprovedbytheGeneralPharmaceuticalFactory,GuangzhouBaiyunMountain,suchastheestablishmentoffivejoint-stockcompaniesthroughtherestructuringofenterprises,inNovember1993asthefirstbatchofGuangzhouCityListedcompanieslistedontheShenzhenStockExchange,nowhastotalsharecapitalof469million.Salesvolumein2007reached3.61billionyuanin2008salesvolumeofover4billionyuan.?companyfocusedonthepharmaceuticalindustry,thebusinessincludestheproductionandmanagementofavarietyofdosageformsofChineseandWesternmedicine,chemicalrawmaterials,externaluse,children'smedicine,healthmedicineandotherdrugs.Afteryearsofdevelopment,undertheWhiteCloudMountainatotalof12membercompanies,haveallpassedthenationalGMP,GSPcertification,GuangzhouBaiyunMountainInnovationCentreChemicalPharmaceuticalEngineeringTechnologyCenterinGuangdongProvince.?thecompanyovertheyearstobrandbuilding,establishingthefirstpharmaceuticalpreparationsinthecountryoneofthebrand,itsbrandawarenessandreputationamongconsumersinthecountryhasastronginfluence.2006"WhiteCloudMountain"trademarkwasidentifiedaswell-knowntrademarksinChinain2007,wasidentifiedas"focusontraininganddevelopmentofexportsofGuangdongProvinceFamousBrand"titlebrandvaluein2008wasassessedtobe10.52billionyuan.
Business:development,production,salesofChineseandWesternmedicine,chemicalrawmaterials,externaluse,children'smedicine,healthmedicine.Operationofcommercialandmaterialsupplyandmarketing.Operatingvarioustypesofgoodsandtechnologyimportandexportbusiness(exceptfornationallimitandprohibition).Managementandfeedprocessingandthe"threetofilla"business.Productionoftwotypesofclinicaltestingoftheinstrumentsanddiagnosticreagents.1.Introduction(2)CompanyBus51.IntroductionMainoperationsbyindustrySub-industryorproductRevenueOperatingcostsGrossmargin(%)OperatingincomeoverlastyearOperatingcostoverlastyearGrossmarginoverlastyearChemicals,pharmaceuticalrawmaterialsmanufacturingindustry43,678.3539,405.269.78%26.74%30.63%-2.69%Chemicalpreparationsmanufacturing193,184.22116,208.4339.85%22.67%15.09%+3.97%ChineseherbalmedicinesandtraditionalChinesemedicineprocessingindustry82,040.3554,892.2433.09%6.48%17.72%-6.39%OtherPharmaceuticalManufacturing614.93624.58-1.57%-12.17%-31.42%+28.51%Pharmaceuticalcommoditycirculation5,684.952,449.0056.92%5.29%9.46%-1.64%Total325,202.80213,579.5134.32%18.22%18.06%+0.09%(3)2010annualoperatingresultsUnit:million
1.IntroductionMainoperations6一、公司介绍(3)annualoperatingresultsin2010Unit:millionMainbusinessbyproductAmoxicillin22,265.9111,471.4648.48%-3.41%6.01%+1.43%Qingkailing27,359.7613,684.5249.98%25.72%34.64%-3.32%YiliKeteling20,778.7618872.159.18%5.49%9.76%-3.53%Cephalosporinsulfideinjection26,499.1513781.0147.99%29.23%37.18%-3.02%Cefixime14,685.914273.9970.90%23.27%20.45%+0.69%CeftriaxoneAPI12,737.8312920.93-1.44%54.41%59.96%-3.52%Cefuroxime10,073.589716.133.55%13.71%16.86%-2.60%(3)2010annualmainbusinessregionsUnit:millionRegionRevenueOperatingincomeoverlastyearSouthChina153171.5715.95%EastChina40378.8130.20%NorthChina39083.7439.35%Northeast11390.0611.15%Southwest28585.8134.39%Northwest4986.6223.38%CentralChina47606.19-1.58%Total325202.818.22%一、公司介绍(3)annualoperatingres7二、共同比分析ComparisonofaccountingdatacalendarUnit:Yuan201020092008Totaloperatingincome3,316,861,029.182,795,105,546.582,635,870,540.72Grossprofit257,089,118.33117,617,343.45115,966,090.00Netprofitattributabletoshareholdersoflistedcompanies204,736,590.14107,765,675.4376,407,343.62DeductionattributabletoshareholdersoftheCompany'snetnon-recurringgainsandlosses163,981,242.9349,316,518.0838,644,489,063.00CashflowfromoperatingactivitiesNet327,214,424.47300,141,134.1683,532,831.99Theendof2010Theendof2009Theendof2008Totalassets3,055,310,511.652,945,054,275.462,814,309,427.45Thereforeattributabletoshareholdersoflistedcompaniestherightsandinterests1,106,532,618.04912,534,940.30804,974,766.55Equity(shares)469,053,689.00469,053,689.00469,053,689.00二、共同比分析Comparisonofaccountin82.CommonratioanalysisLongitudinalanalysisofthecommonratioBalanceSheet
AssetsDecember31,2010December31,2009December31,2008Totalcurrentassets50.05%49.67%45.76%Totalnon-currentassets49.95%50.33%54.24%Totalassets100.00%100.00%100.00%TotalliabilitiesandequityDecember31,2010December31,2009December31,2008Totalcurrentliabilities56.90%62.29%63.55%Totalnon-currentliabilities4.97%4.83%6.03%TotalLiabilities61.87%67.13%69.58%Totalequity38.13%32.87%30.42%Totalliabilitiesandequity100.00%100.00%100.00%2.CommonratioanalysisLongitu92.CommonratioanalysisLongitudinalanalysisofthecommonratioIncomeStatement
IncomeStatementDecember31,2010December31,2009December31,2008Revenue100.00%100.00%100.00%Operatingcosts65.00%65.41%67.40%Businesstaxandsurcharges0.73%0.90%0.83%Sellingexpenses15.46%16.84%15.16%Managementfees11.25%12.07%11.31%Financecosts1.57%2.28%3.62%Impairmentofassets0.10%0.63%0.58%Operatingprofit7.19%3.03%2.77%Grossprofit7.75%4.21%4.40%Netprofit6.60%4.34%3.19%2.CommonratioanalysisLongitu102.CommonratioanalysisSummaryoflongitudinalanalysisofthecommonratio
Companyformorerationaluseoffundsinthefuturedevelopmentofthedebtthecompanyisfacingdown,thecompanyincreasedmobility,improvedabilitytorepaythedebt,theenterprise'sreputationismoresecure.
Companyattachesimportancetotheuseofnewtechnologies,improvetheinternalmanagementmorestreamlined,bettercustomerservice.
Netincomeincreasedtoincreasetheeffectivenessofthecompany,theinvestorshavemoreconfidenceinthestability.2.CommonratioanalysisSummary112.CommonratioanalysisAssetsDecember31,2010December31,2009December31,2008Totalcurrentassets118.72%113.56%100%Totalnon-currentassets99.99%97.12%100%Totalassets108.56%104.65%100%TotalliabilitiesandequityDecember31,2010December31,2009December31,2008Totalcurrentliabilities97.19%102.57%100%Totalnon-currentliabilities89.57%83.86%100%TotalLiabilities96.53%100.95%100%Totalequity136.09%113.10%100%Totalliabilitiesandequity108.56%104.65%100%CommonratioofhorizontalBalanceSheet
2.CommonratioanalysisAssets122.CommonratioanalysisCommonratioofhorizontal
IncomeStatement
IncomeStatementDecember31,2010December31,2009December31,2008Revenue125.84%106.04%100%Operatingcosts121.35%102.91%100%Businesstaxandsurcharges110.37%115.50%100%Sellingexpenses128.37%117.85%100%Managementfees125.08%113.15%100%Financecosts54.77%66.99%100%Impairmentofassets22.29%115.35%100%Operatingprofit326.83%116.09%100%Grossprofit221.69%101.42%100%Netprofit260.83%144.27%100%2.CommonratioanalysisCommon132.CommonratioanalysisSummaryofthecommonratioofhorizontal
Companyformorerobustuseoffundsandreasonable,thecompany'soperationsmoresmoothly,liquidity,solvency,corporatereputation,andotherareashavebeenprotected.Declineinthecompany'sdebt,thecompanyforreducingtheburdenofdebt,moremoneyintothebusinesssales,thecompanyearningscouldincreasefurther.Companyrevenuehasincreasedeachyear,significantlyimprovedtheeffectivenessofthecompany,netincomedoubledup,sothatinvestorshavemoreconfidenceininvestment.Inmanagement,thecompanytendstoimprovethemanagementandthecompany'sstrengthyearafteryearstrong,withinvestorsforgreaterstability.2.CommonratioanalysisSummary143.RelatedRatioAnalysisLiquidity
Units201020092008ThenumberofdaysaccountsreceivablerecoveryDays54.7371.6894.94AccountsreceivableturnoverTimes/year13.3410.187.69AccountsreceivableturnoverdaysDays27.3635.8447.47InventoryturnoverdaysDays101.5793.7495.99BusinessinventoryturnoverTimes/year3.593.893.80InventoryTurnoverDays101.5793.7495.99OperatingcycleDays152.14128.26145.29WorkingcapitalYuan(209326944.93)(371935725.92)(500657936.26)CurrentRatio0.880.790.72QuickRatio0.460.540.45CashRatio9SalesandworkingcapitalratioTimes/year-15.85-7.52-5.26Cashflowfromoperations/currentliabilitiesandcurrentportionoflongtermnotesreceivableandTimes/year4.246.802.543.RelatedRatioAnalysisLiqui153.RelatedRatioAnalysisFlowAnalysisSummarySignificantimprovementinliquidity,andaslidingscaleyearafteryear,verygoodabilitytomorestablecapitalflows.Timelyrecoveryofaccountsreceivable,inventoryflowcapacityincreasedsignificantlyintermsofaccountsreceivableandinventoryistoobtainbetterreturns.
Salesdidnotkeepupwiththepaceofworkingcapital,whichisabadtrend.3.RelatedRatioAnalysisFlow163.RelatedRatioAnalysisLong-termsolvency
Units201020092008InterestcoverTimes5.922.842.22Debtratio%61.8767.1369.58Thegearingratio%162.28204.19228.77Ratioofdebttonettangibleassets%196.01259.34305.88Cashflowfromoperations/totalliabilities%10.7110.192.973.RelatedRatioAnalysisLong-173.RelatedRatioAnalysisSummaryoflong-termsolvencyofThesolvencyofthecompanyverywell,thecreditor'sinterestiswellmaintained.Thecompanyhasagoodreputationthatinthebankstogetfundstohelpbetter.Intheinterestsofcreditorsbankruptcycanbewellmaintained.3.RelatedRatioAnalysisSumma183.RelatedRatioAnalysisProfitability
Units201020092008Netprofitmargin%6.604.343.19TotalassetsturnoverTimes/year1.110.970.95Returnonassets%7.304.213.02Operatingmargin%7.193.032.77OperatingassetturnoverTimes/year1.241.061.01Returnonoperatingassets%8.943.212.79RatioofsalestofixedassetsTimes/year5.514.203.73ROI%20.2613.1210.11Returnontotalequity%13.288.686.70Returnoncommonequity%13.288.686.70Grossprofitmargin%35.0034.5932.603.RelatedRatioAnalysisProfi193.RelatedRatioAnalysisProfitabilityAnalysisSummaryFrom2008to2010,thecompany'sprofitabilitycontinuestoimprove,netinterestmarginandoperatingmarginincreasedsignificantly,thesituationisquitegood.Thehighertheprofitabilitythatinvestorshaveconfidenceinthefuturethecompanyiswillingtopaythepurchasepriceforeachdollarsurplus,thecompanycangetmorerevenue.3.RelatedRatioAnalysisProfi203.RelatedRatioAnalysisInvestorAnalysisUnits201020092008FinancialLeverage1.001.011.02EarningspershareYuan0.43650.22980.1629PE39.2258.3130.13Rateofretainedearnings%94.4691.8891.63Dividendpayoutratio%7.3919.9524.36Dividendyield%2BookvaluepershareYuan2.482.062.45OperatingcashflowpershareYuan0.700.640.18CashFlow/CashDividendTimes/year26.9830.5111.89EndmarketYuan17.1213.404.823.RelatedRatioAnalysisInves213.RelatedRatioAnalysisInvestorAnalysisSummaryShareholdershasincreased,thestockpriceroseyearbyyear.Volatileearnings,agreaterimpactforthecompany.Decliningdividendpaymentwillresultinsomeshareholdersselltheirshares.Betweentheprice-earningsratioisnormalin5-20.Whenthestockmarketarefactorsthatdonotinterferewiththenormal,someofthestockmarketshouldnothavebeenbiduptotheheightofprice-earningsratiowillbetoohigh.Morethan20price-earningsratioisnotconsiderednormal.Thestockpricedeclineislikelyaprecursortohigherrisk.
Asthecompany'slargestshareholder,theproceedswillbegood;andasordinaryshareholders,althoughtheinterestisnotcompromised,butcomparedwiththepreviousincome,willdecline.3.RelatedRatioAnalysisInves224.ComparativeAnalysisofcompetitorsLiquidity
UnitsBaiyunshan2010Yunnanbaiyao2010ThenumberofdaysaccountsreceivablerecoveryDays54.7372.79AccountsreceivableturnoverTimes/year13.3410.03AccountsreceivableturnoverdaysDays27.3636.39InventoryturnoverdaysDays101.5788.38BusinessinventoryturnoverTimes/year3.594.13InventoryTurnoverDays101.5788.38OperatingcycleDays128.94124.77WorkingcapitalYuan(209326944.93)3336109462.96CurrentRatio0.882.10QuickRatio0.461.20CashRatio0.200.66SalesandworkingcapitalratioTimes/year-15.853.02Cashflowfromoperations/currentliabilitiesandcurrentportionoflongtermnotesreceivableandTimes/year4.242.534.ComparativeAnalysisofcom234.ComparativeAnalysisofcompetitorsSummaryofComparativeAnalysisofLiquidity
Inaccountsreceivable,theBaiyunMountainisbetterthanthecompanyYunnanbaiyaocompany.Intheinventory,thecompanyisbetterthantheBaiyunMountainYunnanbaiyaocompany.Inworkingcapital,currentratio,quickratio,cashratio,etc.,YunnanbaiyaocompaniesarebetterthantheWhiteCloudMountainCompany.
Yunnanbaiyaocompany'sliquidityisbetterintheBaiyunMountain,thecompany'sliquidity.Yunnanbaiyaocompaniesbetteraccesstofundsoffundscantakeadvantageoffasterproductionandlowerearnings.4.ComparativeAnalysisofcom244.ComparativeAnalysisofcompetitorsLong-termsolvency
UnitsBaiyunshan2010Yunnanbaiyao2010InterestcoverTimes5.9270.39Debtratio%61.87%42.17%Thegearingratio%162.28%72.91%Ratioofdebttonettangibleassets%196.01%74.94%Cashflowfromoperations/totalliabilities%10.71%5.66%4.ComparativeAnalysisofcom254.ComparativeAnalysisofcompetitorsSummaryComparisonoflong-termsolvency
Indebt,YunnanbaiyaocompanydataarebetterthaneachoftheWhiteCloudMountainCompany,thecompany'ssolvencyratioYunnanbaiyaoBaiyunMountain,thecompany'sabilitytobetterthelot.Yunnanbaiyaobetterthecredibilityofthecompanythatinbanking,financialassistancecanbebetter,andintheinterestsofcreditors,bankruptcycanbewellmaintained.4.ComparativeAnalysisofcom264.ComparativeAnalysisofcompetitorsProfitability
UnitsBaiyunshan2010Yunnanbaiyao2010Netprofitmargin%6.609.19TotalassetsturnoverTimes/year1.111.48Returnonassets%7.3013.58Operatingmargin%7.1910.35OperatingassetturnoverTimes/year1.242.15Returnonoperatingassets%8.9422.29RatioofsalestofixedassetsTimes/year5.51-18.57ROI%20.2623.01Returnontotalequity%13.2814.87Returnoncommonequity%13.2814.87Grossprofitmargin%35.010.274.ComparativeAnalysisofcom274.ComparativeAnalysisofcompetitorsSummaryofComparativeAnalysisofprofitabilityIntermsofprofitability,YunnanbaiyaocompaniesarebetterthanmostofthedatathecompanyBaiyunMountain,onlysalesandgrossmarginratiooffixedassetsislowerthanBaiyunMountainCompany.4.ComparativeAnalysisofcom284.ComparativeAnalysisofcompetitorsInvestorAnalysisUnitsBaiyunshan2010Yunnanbaiyao2010FinancialLeverage1.001.00EarningspershareYuan0.43651.33PE39.2245.41Rateofretainedearnings%94.4699.91Dividendpayoutratio%7.390.10Dividendyield%0.150.0022BookvaluepershareYuan2.487.02OperatingcashflowpershareYuan0.700.62CashFlow/CashDividendTimes/year26.98511.95EndmarketYuan17.1260.404.ComparativeAnalysisofcom294.ComparativeAnalysisofcompetitorsSummaryComparisonofinvestors
WhiteCloudMountainInc.andYunnanbaiyaocompaniesregardthetwocompaniesrelativetotheirowncomparativeadvantagesofinvestors.AttheendofthemarketpricewashigherthanthemarketpriceofthecompanyYunnanbaiyaoBaiyunMountainCompany.Asamajorshareholderintheinvestment,theYunnanbaiyaotogainabetterincome,andinvestmentinthestockasordinaryshareholders,theBaiyunMountainCompanyisthebetterchoice.
Price-earningsratioofthetwocompanieshavemorethan20%,thereisadrasticdropinrisk.4.ComparativeAnalysisofcom305.Conclusions
Incommonthanbylineanalysis,correlationratioanalysisandcomparativeanalysisofcompetitors,thecompanyobtainedthemobilityofBaiyunMountain,thelong-termsolvency,profitability,lowerthantheYunnanbaiyaocompany.Yunnanbaiyaocompanywillbeinvestingalittlebitbetterreturns.Comparisonofinvestorsaftermakingfurtherdrawininvestmentasamajorshareholder,theinvestmentcompanywillbebetterYunnanbaiyaoincome;ordinaryshareholdersbythelineastheinvestment,theinvestmentBaiyunMountaintogainbetterreturns.5.ConclusionsIncommonth315.ConclusionsOverall,theGuangzhouBaiyunMountainPharmaceuticalCo.,Lhedevelopmentorwithinthepastfewyearsshowagoodtrend.Thecompany'scapitalcanhaveagoodrecovery,thecompanyhasgooddistributionchannels.Thecompany'sabilitytorepaydebtrisingtoaverygoodinvestorprotection.Upwardtrendinprofitabilityinthewellcanbeverygoodprofit.Rationalizationofthecompany'sinternalmanagementofmoreandmore,forcustomersandinvestorsisagoodhelp.BaiyunMountainCompanyasanemergingpharmaceuticalcompany,isthecauseoftheriseinthecompany,therearegoodprospectsfordevelopmentinthefuturedevelopmentofthecompanystillhasgooddevelopmentprospects.Inthefuture,therequirementsofthepeoplefortheirownhealthgraduallyimproved,theBaiyunMountain,thecompanystillhasaverygooddevelopmentofthismarket.AlsoofgreatimportancetotraditionalChinesemedicine,BaiyunMountainisthenationalpolicyinthisareainpossessionofgoodadvantage.5.ConclusionsOverall,theGua32ThanksThanks33Financialanalysiscoursework
GuangzhouBaiyunshanPharmaceuticalCo.,Ltd.2010AnnualReportAnalysis————InternationalInstituteofAccounting0803
Financialanalysiscoursework34TeammembersTeammembers35AnalysisOutline1.Introduction2.Commonratioanalysis3.RelatedRatioAnalysis4.ComparativeAnalysisofcompetitors5.ConclusionsAnalysisOutline1.Introducti361.Introduction(1)BasicinformationofcompanyChineseCompanyName:GuangzhouBaiyunshanPharmaceuticalCo.,Ltd.NameinEnglish:GuangzhouBaiyunshanPharmaceuticalCo.,Ltd.Chineseabbreviationofthecompany:BaiyunshanPharmaceuticalCompanyabbreviation:BYSLegalrepresentative:Mr.XieBinBoardSecretary:Mr.QiaoYongAddress:BaiyunDistrict,GuangzhouCity,GuangdongProvince,andthestreetwith88YunxiangRoadPhoneax:020-87,063,699E-mail:qiaoyong@SecuritiesAffairsRepresentative:MissGaoYanzhuAddress:BaiyunDistrict,GuangzhouCity,GuangdongProvince,andthestreetwith88YunxiangRoadPhoneax:020-87,063,699E-mail:gyzh2611@126.com1.Introduction(1)Basicinfor371.Introduction(2)CompanyBusinessDescriptionGuangzhouBaiyunshanPharmaceuticalCo.,Ltd.Establishedin1973,1992,GuangzhouMunicipalPeople'sGovernmentof11menstrualapprovedbytheGeneralPharmaceuticalFactory,GuangzhouBaiyunMountain,suchastheestablishmentoffivejoint-stockcompaniesthroughtherestructuringofenterprises,inNovember1993asthefirstbatchofGuangzhouCityListedcompanieslistedontheShenzhenStockExchange,nowhastotalsharecapitalof469million.Salesvolumein2007reached3.61billionyuanin2008salesvolumeofover4billionyuan.?companyfocusedonthepharmaceuticalindustry,thebusinessincludestheproductionandmanagementofavarietyofdosageformsofChineseandWesternmedicine,chemicalrawmaterials,externaluse,children'smedicine,healthmedicineandotherdrugs.Afteryearsofdevelopment,undertheWhiteCloudMountainatotalof12membercompanies,haveallpassedthenationalGMP,GSPcertification,GuangzhouBaiyunMountainInnovationCentreChemicalPharmaceuticalEngineeringTechnologyCenterinGuangdongProvince.?thecompanyovertheyearstobrandbuilding,establishingthefirstpharmaceuticalpreparationsinthecountryoneofthebrand,itsbrandawarenessandreputationamongconsumersinthecountryhasastronginfluence.2006"WhiteCloudMountain"trademarkwasidentifiedaswell-knowntrademarksinChinain2007,wasidentifiedas"focusontraininganddevelopmentofexportsofGuangdongProvinceFamousBrand"titlebrandvaluein2008wasassessedtobe10.52billionyuan.
Business:development,production,salesofChineseandWesternmedicine,chemicalrawmaterials,externaluse,children'smedicine,healthmedicine.Operationofcommercialandmaterialsupplyandmarketing.Operatingvarioustypesofgoodsandtechnologyimportandexportbusiness(exceptfornationallimitandprohibition).Managementandfeedprocessingandthe"threetofilla"business.Productionoftwotypesofclinicaltestingoftheinstrumentsanddiagnosticreagents.1.Introduction(2)CompanyBus381.IntroductionMainoperationsbyindustrySub-industryorproductRevenueOperatingcostsGrossmargin(%)OperatingincomeoverlastyearOperatingcostoverlastyearGrossmarginoverlastyearChemicals,pharmaceuticalrawmaterialsmanufacturingindustry43,678.3539,405.269.78%26.74%30.63%-2.69%Chemicalpreparationsmanufacturing193,184.22116,208.4339.85%22.67%15.09%+3.97%ChineseherbalmedicinesandtraditionalChinesemedicineprocessingindustry82,040.3554,892.2433.09%6.48%17.72%-6.39%OtherPharmaceuticalManufacturing614.93624.58-1.57%-12.17%-31.42%+28.51%Pharmaceuticalcommoditycirculation5,684.952,449.0056.92%5.29%9.46%-1.64%Total325,202.80213,579.5134.32%18.22%18.06%+0.09%(3)2010annualoperatingresultsUnit:million
1.IntroductionMainoperations39一、公司介绍(3)annualoperatingresultsin2010Unit:millionMainbusinessbyproductAmoxicillin22,265.9111,471.4648.48%-3.41%6.01%+1.43%Qingkailing27,359.7613,684.5249.98%25.72%34.64%-3.32%YiliKeteling20,778.7618872.159.18%5.49%9.76%-3.53%Cephalosporinsulfideinjection26,499.1513781.0147.99%29.23%37.18%-3.02%Cefixime14,685.914273.9970.90%23.27%20.45%+0.69%CeftriaxoneAPI12,737.8312920.93-1.44%54.41%59.96%-3.52%Cefuroxime10,073.589716.133.55%13.71%16.86%-2.60%(3)2010annualmainbusinessregionsUnit:millionRegionRevenueOperatingincomeoverlastyearSouthChina153171.5715.95%EastChina40378.8130.20%NorthChina39083.7439.35%Northeast11390.0611.15%Southwest28585.8134.39%Northwest4986.6223.38%CentralChina47606.19-1.58%Total325202.818.22%一、公司介绍(3)annualoperatingres40二、共同比分析ComparisonofaccountingdatacalendarUnit:Yuan201020092008Totaloperatingincome3,316,861,029.182,795,105,546.582,635,870,540.72Grossprofit257,089,118.33117,617,343.45115,966,090.00Netprofitattributabletoshareholdersoflistedcompanies204,736,590.14107,765,675.4376,407,343.62DeductionattributabletoshareholdersoftheCompany'snetnon-recurringgainsandlosses163,981,242.9349,316,518.0838,644,489,063.00CashflowfromoperatingactivitiesNet327,214,424.47300,141,134.1683,532,831.99Theendof2010Theendof2009Theendof2008Totalassets3,055,310,511.652,945,054,275.462,814,309,427.45Thereforeattributabletoshareholdersoflistedcompaniestherightsandinterests1,106,532,618.04912,534,940.30804,974,766.55Equity(shares)469,053,689.00469,053,689.00469,053,689.00二、共同比分析Comparisonofaccountin412.CommonratioanalysisLongitudinalanalysisofthecommonratioBalanceSheet
AssetsDecember31,2010December31,2009December31,2008Totalcurrentassets50.05%49.67%45.76%Totalnon-currentassets49.95%50.33%54.24%Totalassets100.00%100.00%100.00%TotalliabilitiesandequityDecember31,2010December31,2009December31,2008Totalcurrentliabilities56.90%62.29%63.55%Totalnon-currentliabilities4.97%4.83%6.03%TotalLiabilities61.87%67.13%69.58%Totalequity38.13%32.87%30.42%Totalliabilitiesandequity100.00%100.00%
温馨提示
- 1. 本站所有资源如无特殊说明,都需要本地电脑安装OFFICE2007和PDF阅读器。图纸软件为CAD,CAXA,PROE,UG,SolidWorks等.压缩文件请下载最新的WinRAR软件解压。
- 2. 本站的文档不包含任何第三方提供的附件图纸等,如果需要附件,请联系上传者。文件的所有权益归上传用户所有。
- 3. 本站RAR压缩包中若带图纸,网页内容里面会有图纸预览,若没有图纸预览就没有图纸。
- 4. 未经权益所有人同意不得将文件中的内容挪作商业或盈利用途。
- 5. 人人文库网仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对用户上传分享的文档内容本身不做任何修改或编辑,并不能对任何下载内容负责。
- 6. 下载文件中如有侵权或不适当内容,请与我们联系,我们立即纠正。
- 7. 本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。
最新文档
- 班组准入管理办法
- 疫情价格管理办法
- 电子凭证管理办法
- 种子农药管理办法
- 生鲜采购管理办法
- 2025装饰设计合同协议范本
- 2025钻孔灌注桩施工劳务分包合同
- 管理办法法制审核
- 矿车使用管理办法
- 防水工程建筑劳务合同范本2025年
- DL∕T 1901-2018 水电站大坝运行安全应急预案编制导则
- 起重机行业市场分析报告2024年
- 北京联合大学微观经济学期末试卷
- 培训师破冰小游戏含内容
- 智研咨询发布:锦纶纤维行业市场动态分析、发展方向及投资前景分析报告
- DB32T 4401-2022《综合医院建筑设计标准》
- 中医培训课件:《放血疗法》
- 液压滑模施工资料
- 小区自助洗车项目计划方案
- 2024-2029全球及中国苯丙酮尿症(PKU)行业市场发展分析及前景趋势与投资发展研究报告
- 注塑车间加料员培训课件
评论
0/150
提交评论